Clinical trials: Essential Hypertension
Hypertension
A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension
This study will evaluate the long-term gastrointestinal (GI) safety and efficacy of aliskiren (300 mg) compared to ramipril (10mg) in patients ≥ 50 years with essential hypertension.
- Trial name
- NCT00631917
- Testing
- Aliskiren, Ramipril
- Where
- 7 sites in United States, Argentina and 5 more
- Volunteers
- 774 people
- Sponsor
- Novartis
Mild to Severe Hypertension
MK0954A-264 Filter Study (0954A-264)(COMPLETED)
To compare the blood pressure lowering efficacy, safety and tolerability of a combination drug to a single drug taken once daily in patients with uncontrolled blood pressure following a 4-week filter on the single therapy product.
- Trial name
- NCT00307060
- Testing
- MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 6 weeks, losartan / Duration of Treatment: 6 weeks
- Volunteers
- 274 people
- Sponsor
- Organon and Co
Hypertension
A Comparative Study Between Amlodipine 10mg And 5mg With Hypertension For Whom 5mg Is Insufficient
The changes in the trough systolic blood pressure from the baseline were assessed after 8 weeks of double-blind treatment with amlodipine 10 mg or amlodipine 5 mg
- Trial name
- NCT00415623
- Testing
- Amlodipine
- Where
- 14 sites in Japan
- Volunteers
- 305 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Essential Hypertension
Effects of Remote Ischemic Conditioning on Blood Pressure in Older Patients With Hypertension
The purpose of this study is to learn about effects of remote ischemic conditioning on blood pressure in older patients with essential hypertension.
- Trial name
- NCT05845905
- Testing
- Remote ischemic conditioning
- Where
- China
- Volunteers
- 158 people
- Sponsor
- Yi Yang
Essential Hypertension, Primary Hypercholesterolemia
To Evaluate the Renal Protective Effects and Safety of 'Fimasartan and Atorvastatin' or 'Fimasartan, Atorvastatin and Ezetimibe'.
This prospective study aims to observe changes in renal function and related parameters in patients with essential hypertension and primary hypercholesterolemia receiving either the combination of fimasartan and atorvastatin or…
- Trial name
- NCT07685054
- Volunteers
- 12,700 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
Efficacy and Safety of Remote Ischemic Conditioning in the Treatment of Essential Hypertension (RICBP-EH)
The purpose of this study is to determine the efficacy and safety of remote ischemic conditioning in the treatment of essential hypertension.
- Trial name
- NCT05910242
- Testing
- Remote ischemic conditioning
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Yi Yang
Primary Hyperaldosteronism
Primary Hyperaldosteronism and Ischemia-reperfusion Injury
Patients with primary hyperaldosteronism experience more cardiovascular events compared to patients with primary hypertension, independent of the blood pressure level.
- Trial name
- PHA-FMD (NCT01978132)
- Testing
- forearm ischemia and reperfusion
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Radboud University Medical Center
Hypertension,Essential
Licorice and Home Blood Pressure, Additional Study
Out-of-office blood pressure is more strongly associated with cardiovascular risk than office blood pressure. Licorice is known to raise blood pressure, but no previous studies have measured the effects on home blood pressure.
- Trial name
- NCT06019598
- Testing
- Licorice
- Where
- Sweden
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Linkoeping University
Type 2 Diabetes Mellitus, Diabetic Nephropathy
Effects of Spironolactone Combination Therapy on Proteinuria, Kidney Function, and Blood Pressure
The detrimental effects of aldostrone are not adequately arrested by the use of angiotensin converting enzyme (ACE), angiotensin II receptor blocker (ARB) or a combination of both.
- Conditions
- Type 2 Diabetes Mellitus, Diabetic Nephropathy, Essential Hypertension
- Trial name
- NCT01667614
- Testing
- spironolacone 25 mg tablets added to losartan
- Where
- Iran
- Volunteers
- 136 people
- Sponsor
- Tehran University of Medical Sciences
Primary Hypertension
A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227B
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-227 in healthy subjects.
- Trial name
- NCT06884085
- Testing
- Co-administration of AD-227A and AD-227B, Administration of AD-227
- Where
- South Korea
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Hypertension, Systolic, Cerebrovascular Disease
Intensive Versus Standard Blood Pressure Lowering to Prevent Functional Decline in Older People
This randomized clinical trial examines if lowering and maintaining 24-hour ambulatory systolic blood pressure to <130 mmHg (intensive control) versus <145 mmHg (standard control) slows/halts the progression of deterioration of…
- Trial name
- NCT01650402
- Testing
- Anti-hypertensive therapy to SBP 130 mm Hg, Anti-hypertensive therapy to SBP 145 mm Hg
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- UConn Health
Essential Hypertension
Personal Activity Intelligence in the Treatment of High Blood Pressure
Personal Activity Intelligence (PAI) is a novel metric developed to quantify the amount of routine physical activity (PA) needed to improve health and reduce cardiovascular (CV) mortality.
- Trial name
- NCT04151537
- Testing
- Personal Activity Intelligence, Physical Activity Guidelines
- Where
- Norway
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Norwegian University of Science and Technology
Hypertension
Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan Monotherapy
The objective of this trial is to demonstrate that the fixed dose combination of telmisartan 40 mg and HCTZ 12.5 mg is superior to the monocomponent of telmisartan (Micardis, Gliosartan, Kinzal, Kinzalmono, Predxal, Pritor…
- Trial name
- NCT00144222
- Testing
- Telmisartan 40 mg/HCTZ 12.5 mg, Telmisartan 40 mg
- Where
- 2 sites in Japan
- Volunteers
- 218 people
- Sponsor
- Boehringer Ingelheim
Essential Hypertension
A Study to Evaluate the Effect of Fimasartan on Pharmacokinetics, and the Safety of Digoxin in Healthy Male Volunteers
The purpose of this study is to evaluate the effect of fimasartan on pharmacokinetics, and the safety of digoxin.
- Trial name
- NCT00991783
- Testing
- Digoxin + Fimasartan
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension
This study is an exploratory Phase 1 randomized, double-blind (Investigator and study subject and 2-D echo endpoint assessor), placebo-controlled single IV infusion dose escalation study that will enroll up to approximately 32…
- Trial name
- NCT01873885
- Testing
- Experimental: Single IV Infusion Vasomera (PB1046)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Essential Hypertension
Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension
This study was a non-interventional, secondary use of data, retrospective, cohort study, and the data to be extracted in this study was used as secondary use of collected patient information in the database (Japan Medical Data…
- Trial name
- NCT06604897
- Where
- United States
- Volunteers
- 1,405 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension
Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/Allisartan
The main objective of the study will be to assess the efficacy and safety of Sacubitril/Allisartan (240mg) and Amlodipine (5mg) in patients with essential hypertension uncontrolled after 4-week treatment with…
- Trial name
- NCT07704697
- Testing
- Experimental: Sacubitril/Allisartan and Amlodipine Group, Active Comparator: Sacubitril/Allisartan Group
- Where
- China
- Volunteers
- 346 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Hypertension
Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension
Assess the long-term safety and tolerability of aliskiren, with the optional addition of HCTZ, in patients with essential hypertension, to ensure long term blood pressure control and protect against end organ damage.
- Trial name
- NCT00219037
- Testing
- aliskiren
- Where
- Germany
- Volunteers
- 1,955 people
- Sponsor
- Novartis
Hypertension
Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension
The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil, once daily (QD), compared to ramipril for treating Essential Hypertension.
- Trial name
- NCT00760214
- Testing
- Azilsartan medoxomil, Ramipril
- Where
- 72 sites in Bulgaria, Estonia and 8 more
- Volunteers
- 885 people
- Sponsor
- Takeda
Hypertension,Essential, Exercise Activity
Effect of High-Intensity Interval Training Compared to Hydrochlorothiazide on Ambulatory Blood Pressure
The number of persons with hypertension is increasing and with it the number of related cardiovascular events and related functional or cognitive declines.
- Trial name
- DIISCCO (NCT04103411)
- Testing
- 24h-Ambulatory Blood Pressure
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Anil Nigam